Tissue Spray Probe industry trends over the past 12‑18 months reflect accelerating consolidation and innovation. In March 2024, MedTech Innovations partnered with BioSpray Systems to co‑develop a next‑generation nano‑atomizer that delivers uniform sub‑micron droplets, a move aimed at expanding intra‑operative applications. July 2024 saw the acquisition of NanoMist Labs by Global Diagnostics, adding proprietary piezo‑electric spray technology to its portfolio and broadening its geographic reach into APAC. In September 2024, AeroPharma launched the “Pulse‑Jet” probe, featuring real‑time pressure feedback and a disposable cartridge, which has already secured FDA Class II clearance. Regulatory momentum continued with the EU’s updated Medical Device Regulation (MDR) 2024 amendment, tightening biocompatibility testing for aerosol‑based devices and prompting manufacturers to redesign packaging. Meanwhile, hospital procurement data reveal a shift toward single‑use, sterile probes, driving a 22 % increase in consumable sales YoY. Finally, a $45 million Series B round led by HealthVentures enabled SpectraSpray to scale its manufacturing facility in Texas, targeting a 30 % capacity boost by Q4 2025.
